drugset / Trial / NCT02238314
Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective was to evaluate the antiviral activity and safety of two regimens of tipranavir (500 mg BID or 1000 mg BID) plus ritonavir (100 mg BID) administered in combination with 1 new nucleoside reverse transcriptase inhibitor (NRTI) + efavirenz in multiple protease-inhibitor-experienced HIV-1 positive patients.
Timeline
- Start
- 1999-01
- Primary completion
- 2001-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tipranavir | Small molecule | 500 mg | — |
| Subject | Tipranavir | Small molecule | 1000 mg | — |
| Background | Ritonavir | Other / unclassified | 100 mg | — |